Type-1 cannabinoid receptor (CB1), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both central nervous system and peripheral tissues. Today, its biochemical identification and pharmacological characterization, as well as the screening of thousands of novel ligands that might be useful for developing CB1-based therapies, are the subject of intense research. Among available techniques that allow the analysis of CB1 binding activity, radioligand-based assays represent one of the best, fast, and reliable methods.Here, we describe radioligand binding methods standardized in our laboratory to assess CB1 binding in both tissues and cultured cells. We also report a high-throughput radioligand binding assay that allows to evaluate efficacy and potency of different compounds, which might represent the basis for the development of new drugs that target CB1 receptor-dependent human diseases.

Catani, V., Gasperi, V. (2016). Assay of CB1 receptor binding. In Endocannabinoid Signaling (pp. 41-55). Springer New York [10.1007/978-1-4939-3539-0_5].

Assay of CB1 receptor binding

Catani, VM;GASPERI, VALERIA
2016-01-01

Abstract

Type-1 cannabinoid receptor (CB1), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both central nervous system and peripheral tissues. Today, its biochemical identification and pharmacological characterization, as well as the screening of thousands of novel ligands that might be useful for developing CB1-based therapies, are the subject of intense research. Among available techniques that allow the analysis of CB1 binding activity, radioligand-based assays represent one of the best, fast, and reliable methods.Here, we describe radioligand binding methods standardized in our laboratory to assess CB1 binding in both tissues and cultured cells. We also report a high-throughput radioligand binding assay that allows to evaluate efficacy and potency of different compounds, which might represent the basis for the development of new drugs that target CB1 receptor-dependent human diseases.
2016
Settore BIO/10 - BIOCHIMICA
English
Rilevanza internazionale
Capitolo o saggio
CP55.940; Filtration assay; Radioligand-receptor binding; SR141716; Type-1 cannabinoid receptor
Catani, V., Gasperi, V. (2016). Assay of CB1 receptor binding. In Endocannabinoid Signaling (pp. 41-55). Springer New York [10.1007/978-1-4939-3539-0_5].
Catani, V; Gasperi, V
Contributo in libro
File in questo prodotto:
File Dimensione Formato  
2016. Catani & Gasperi MiMB.pdf

solo utenti autorizzati

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 430.99 kB
Formato Adobe PDF
430.99 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/174221
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 10
  • ???jsp.display-item.citation.isi??? ND
social impact